Literature DB >> 19709480

Neuromodulation versus medication for overactive bladder: the case for early intervention.

Frank N Burks1, Kenneth M Peters.   

Abstract

Overactive bladder (OAB) affects millions of people in the United States, and as the population ages, the prevalence of OAB will invariably increase. Conventional therapy for OAB includes behavioral modification and anticholinergic medication. OAB treatment comes with significant economic impact. With anticholinergic medications often resulting in significant adverse effects and treatment failures, neuromodulation offers an effective treatment modality that is durable and minimally invasive. We argue that neuromodulation, with its high rate of success and significant rate of patient satisfaction, should be offered early in the course of OAB treatment. In addition to sacral neuromodulation, tibial nerve stimulation and chemical neuromodulation offer effective alternative methods of neuromodulation. Neuromodulation is a well-established treatment for "refractory" OAB that deserves a place among traditional treatments for OAB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19709480     DOI: 10.1007/s11934-009-0054-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  43 in total

1.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Authors:  D M Schmid; P Sauermann; M Werner; B Schuessler; N Blick; M Muentener; R T Strebel; D Perucchini; D Scheiner; G Schaer; H John; A Reitz; D Hauri; B Schurch
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

Review 2.  The overactive bladder: Epidemiology and morbidity.

Authors:  Shachi Tyagi; Catherine A Thomas; Yukio Hayashi; Michael B Chancellor
Journal:  Urol Clin North Am       Date:  2006-11       Impact factor: 2.241

3.  Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators.

Authors:  Bertil F M Blok; Jan Groen; J L H Ruud Bosch; Dick J Veltman; Adriaan A Lammertsma
Journal:  BJU Int       Date:  2006-10-11       Impact factor: 5.588

4.  Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study.

Authors:  H C Klingler; A Pycha; J Schmidbauer; M Marberger
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

5.  Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience.

Authors:  Suzette E Sutherland; Ann Lavers; Angeline Carlson; Cindy Holtz; Jyothi Kesha; Steven W Siegel
Journal:  Neurourol Urodyn       Date:  2007       Impact factor: 2.696

6.  Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury.

Authors:  Mohit Khera; George T Somogyi; Susanna Kiss; Timothy B Boone; Christopher P Smith
Journal:  Neurochem Int       Date:  2004-12       Impact factor: 3.921

7.  Safety of MRI at 1.5Tesla in patients with implanted sacral nerve neurostimulator.

Authors:  Mohamed S Elkelini; Magdy M Hassouna
Journal:  Eur Urol       Date:  2006-03-03       Impact factor: 20.096

Review 8.  Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential.

Authors:  Michael B Chancellor; Fernando de Miguel
Journal:  Geriatrics       Date:  2007-05

Review 9.  Muscarinic receptor antagonists for overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson
Journal:  BJU Int       Date:  2007-11       Impact factor: 5.588

10.  Evaluation and management of malfunctioning sacral neuromodulator.

Authors:  Darlene M Gaynor-Krupnick; Neil T Dwyer; Helen Rittenmeyer; Karl J Kreder
Journal:  Urology       Date:  2006-02       Impact factor: 2.649

View more
  3 in total

Review 1.  Sacral nerve modulation in overactive bladder.

Authors:  John A Occhino; Steven W Siegel
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

2.  Patients with medication-refractory OAB symptoms should be further treated with neuromodulation.

Authors:  Jerzy B Gajewski
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

Review 3.  Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review.

Authors:  Gabriele Gaziev; Luca Topazio; Valerio Iacovelli; Anastasios Asimakopoulos; Angelo Di Santo; Cosimo De Nunzio; Enrico Finazzi-Agrò
Journal:  BMC Urol       Date:  2013-11-25       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.